Share this article and save a life!
Medicare just opened the door to CBD. This changes everything.
On April 1, 2026, CMS quietly dropped a bombshell: Medicare pilots will now cover hemp and CBD products in certain alternative payment models.
Think about that for a second.
The same program that wouldn’t cover hearing aids for decades just approved cannabinoid therapies through their new Substance Access Beneficiary Engagement Incentive (BEI).
This isn’t just about CBD oils and creams. This is about recognizing what 70% of seniors already know: traditional pain management often fails them.
Consider the timing:
• 32 million Americans have osteoarthritis
• Opioid prescriptions for seniors dropped 45% since 2019
• CBD market for seniors grew 300% in the last 3 years
• Medicare spent $4.6 billion on pain management last year
But here’s what fascinates me most:
CMS is limiting this to alternative payment models, not fee-for-service Medicare. They’re essentially saying, “Show us the outcomes first.”
Smart? Maybe. Cautious? Definitely.
The real winners here? Value-based care organizations who can now offer seniors what they’ve been buying out-of-pocket anyway. FQHCs serving older adults. ACOs focused on chronic pain management.
The losers? Traditional pain clinics stuck in the opioid-or-nothing mindset.
💡 Here’s my take:
This pilot isn’t just about CBD. It’s CMS admitting that patient preferences matter more than regulatory comfort zones. When 38 states have medical cannabis programs but Medicare wouldn’t touch it, something had to give.
Watch for three things:
1. Which ACOs jump on this first
2. How they measure “clinical guidance alignment”
3. Whether commercial insurers follow suit
The question isn’t whether this will expand beyond pilots. It’s how fast.
Because when Medicare moves, the entire healthcare system follows.
♻️ Repost if chronic pain management needs more therapeutic options.
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
